| 主权项 |
1. A method for the treatment of a solid tumor cancer of: the stomach, the kidneys, the head and neck, the oesophagus, the thyroid, the intestines, the liver, the brain, the urogenital tract, the lung, the pancreas, the colon or the breast; comprising administering to a host in need thereof a Met kinase inhibiting effective amount of a compound of formula I in which D denotes a five- or six-membered unsaturated or aromatic heterocycle having 1 to 3 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by Hal and/or A, R1 denotes OH, OA, O[C(R5)2]nAr, O[C(R5)2]nHet, O[C(R5)2]pN(R5)2, N(R5)2, NR5[C(R5)2]nAr, NR5[C(R5)2]nHet, NR5[C(R5)2]pN(R5)2, COOR5, CON(R5)2, CONR5[C(R5)2]pN(R5)2, CONR5[C(R5)2]pOR5, CONR5[C(R5)2]nHet, COHet or COA, R2 denotes H, A, Hal, OH, OA, N(R5)2, N═CR5N(R5)2, SR5, NO2, CN, COOR5, CON(R5)2, NR5COA, NR5SO2A, SO2N(R5)2, S(O)mA, [C(R5)2]nN(R5)2, [C(R5)2]nHet, O[C(R5)2]pN(R5)2, O[C(R5)2]nHet, S[C(R5)2]pN(R5)2, S[C(R5)2]nHet, NR5[C(R5)2]pN(R5)2, —NR5[C(R5)2]nHet, NHCON(R5)2, NHCONH[C(R5)2]pN(R5)2, NHCONH[C(R5)2]nHet, NHCO[C(R5)2]p—N(R5)2, NHCO[C(R5)2]nHet, CON(R5)2, CONR5[C(R5)2]pN(R5)2, CONR5[C(R5)2]nHet, COHet, COA, O[C(R5)2]nNR5COZ, O[C(R5)2]nNR2COHet1, O[C(R5)2]nCyc[C(R5)2]nN(R5)2, O[C(R5)2]nCyc[C(R5)2]nOR5, O[C(R5)2]nCyc[C(R5)2]nHet1,O[C(R5)2]nCR5 (NR5)2COOR5, O[C(R5)2]nNR5CO[C(R5)2]nNR5COA, O[C(R5)2]nNR5COOA, O[C(R5)2]nCO—NR5-A, O[C(R5)2]nCO—NR5-[C(R5)2]nHet1, O[C(R5)2]nCONH2, O[C(R5)2]nCONHA, O[C(R5)2]nCONA2, O[C(R5)2]nCO—NR5-[C(R2)2]nN(R5)2 or OCOA,
Z denotes CR5(NR5)2CR5(OR5)A, R3 denotes H or A, R4 denotes H, A or Hal, R5 denotes H or A′, A denotes unbranched or branched alkyl having 1-10 C atoms,
in which 1-7 H atoms may be replaced by OH, F, Cl and/or Br, and/or in which one or two CH2 groups may be replaced by O, NH, S, SO, SO2 and/or CH═CH groups,or cyclic alkyl having 3-7 C atoms, in which 1-7 H atoms may be replaced by OH, F, Cl and/or Br, A′ denotes unbranched or branched alkyl having 1-6 C atoms, in which 1-5 H atoms may be replaced by F, Cyc denotes cycloalkylene having 3-7 C atoms, Ar denotes phenyl, naphthyl or biphenyl, each of which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OR5, N(R5)2, SR5, NO2, CN, COOR5, CON(R5)2, NRSCOA, NR5SO2A, SO2N(R5)2, S(O)mA, CO-Het1, [C(R5)2]nN(R5)2, [C(R5)2]nHet1, O[C(R5)2]p—N(R5)2, O[C(R5)2]nHet1, NHCOOA, NHCON(R5)2, NHCOO[C(R5)2]pN(R5)2, NHCOO[C(R5)2]nHet1, NHCONH[C(R5)2]pN(R5)2, NHCONH[C(R5)2]nHet1, OCONH[C(R5)2]pN(R5)2 and/or OCONH[C(R5)2]nHet1, Het denotes a mono-, bi- or tricyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by Hal, A, OR5, N(R5)2, SR5, NO2, CN, COOR5, CON(R5)2, NRSCOA, NR5SO2A, SO2N(R5)2, S(O)mA, CO-Het1, [C(R5)2]nN(R5)2, [C(R5)2]nHet1, O[C(R5)2]pN(R5)2, O[C(R5)2]nHet1, NHCOOA, NHCON(R5)2, NHCOO[C(R5)2]pN(R5)2, NHCOO[C(R5)2]nHet1, NHCONH[C(R5)2]pN(R5)2, NHCONH[C(R5)2]nHet1, OCONH[C(R5)2]pN(R5)2, OCONH[C(R5)2]nHet1, CO-Het1, CHO, COA, ═S, ═NH, ═NA and/or ═O (carbonyl oxygen), Het1 denotes a monocyclic saturated heterocycle having 1 to 2 N and/or O atoms, which may be mono- or disubstituted by A, OA, OH, Hal and/or ═O (carbonyl oxygen), Hal denotes F, Cl, Br or I, m denotes 0, 1 or 2, n denotes 0, 1, 2, 3 or 4, p denotes 2, 3, 4, 5, or 6, q denotes 1, 2, 3, 4 or 5, or a pharmaceutically usable salt, tautomer or stereoisomer thereof, including mixtures thereof in all ratios. |
